These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 32621557

  • 1. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
    McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, Van de Werf F, Green JB, Armstrong PW, Holman RR, TECOS Study Group.
    Eur J Heart Fail; 2020 Nov; 22(11):2026-2034. PubMed ID: 32621557
    [Abstract] [Full Text] [Related]

  • 2. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS, Zheng Y, Green JB, Armstrong PW, Westerhout CM, McGuire DK, Cornel JH, Holman RR, Peterson ED.
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [Abstract] [Full Text] [Related]

  • 3. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
    Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group.
    N Engl J Med; 2015 Jul 16; 373(3):232-42. PubMed ID: 26052984
    [Abstract] [Full Text] [Related]

  • 5. Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification.
    Lawson CA, Jones PW, Teece L, Dunbar SB, Seferovic PM, Khunti K, Mamas M, Kadam UT.
    JACC Heart Fail; 2018 Jan 16; 6(1):18-26. PubMed ID: 29032131
    [Abstract] [Full Text] [Related]

  • 6. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 7. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr 03; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 8. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
    Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, Toto RD, Wanner C, Espeland MA, Mattheus M, Schnaidt S, Perkovic V, Gollop ND, McGuire DK.
    JAMA Cardiol; 2024 Feb 01; 9(2):134-143. PubMed ID: 38170502
    [Abstract] [Full Text] [Related]

  • 9. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
    Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, TECOS Study Group.
    Circulation; 2017 Sep 26; 136(13):1193-1203. PubMed ID: 28626088
    [Abstract] [Full Text] [Related]

  • 10. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Pagidipati NJ, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED, TECOS Study Group.
    Am Heart J; 2020 Jan 26; 219():47-57. PubMed ID: 31707324
    [Abstract] [Full Text] [Related]

  • 11. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
    Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR.
    Am Heart J; 2013 Dec 26; 166(6):983-989.e7. PubMed ID: 24268212
    [Abstract] [Full Text] [Related]

  • 12. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2018 Oct 26; 20(10):2379-2388. PubMed ID: 29923323
    [Abstract] [Full Text] [Related]

  • 13. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
    Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2018 Mar 26; 41(3):596-603. PubMed ID: 29311155
    [Abstract] [Full Text] [Related]

  • 14. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2017 Apr 26; 40(4):494-501. PubMed ID: 28057693
    [Abstract] [Full Text] [Related]

  • 15. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
    Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW, TECOS Study Group.
    Diabetes Obes Metab; 2017 Jan 26; 19(1):78-86. PubMed ID: 27607571
    [Abstract] [Full Text] [Related]

  • 16. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
    Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2017 Dec 26; 40(12):1763-1770. PubMed ID: 28986504
    [Abstract] [Full Text] [Related]

  • 17. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
    Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e014328. PubMed ID: 31852422
    [Abstract] [Full Text] [Related]

  • 18. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
    Huang CJ, Wang WT, Sung SH, Chen CH, Lip GYH, Cheng HM, Chiang CE.
    Diabetes Obes Metab; 2018 Sep 07; 20(9):2131-2139. PubMed ID: 29722116
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Green JB, Everett BM, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi SE, Pokharel Y, Schade D, Scrymgeour A, Tan MH, Utzschneider KM, Mudaliar S, GRADE Study Research Group.
    Circulation; 2024 Mar 26; 149(13):993-1003. PubMed ID: 38344820
    [Abstract] [Full Text] [Related]

  • 20. Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
    Bethel MA, Sourij H, Stevens SR, Hannan K, Lokhnygina Y, Adler AI, Peterson ED, Holman RR, Lopes RD.
    Cardiovasc Diabetol; 2023 Mar 28; 22(1):72. PubMed ID: 36978066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.